 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Collegium Pharmaceutical, Inc. (COLL) develops and commercializes medicines for pain management. 
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
Shares have formed a bullish "cup and handle" and higher share prices are expected. On November 3rd, COLL reported 3rd Quarter September 2022 earnings of $0.96 per share on revenue of $127.0 million. The consensus earnings estimate was $1.04 per share on revenue of $125.1 million. Revenue grew 61.1% on a year-over-year basis.
Guided Higher: The company said it expects 2022 revenue of $455.0 million to $465.0 million. The company's previous guidance was revenue of $450.0 million to $465.0 million and the previous consensus revenue estimate was $458.09 million for the year ending December 31, 2022.
The company reports on February 2nd.
Entry Point: $22.75
Stop Loss: $21.50
Trading Range: $14.04 to $23.34
Target Price: $25.75
